このページの読み込み中にエラーが発生したようです.
当社チームに通知しましたが、問題が続くようでしたらEメールサポートウィジェットを使ってご連絡ください。
| Trend | Peers | Company |
|---|---|---|
| Is return on equity increasing? | Yes | No |
| Is net profit margin increasing? | No | No |
| Is asset turnover increasing? | No | No |
| Is equity multiplier increasing? | No | No |
| Competitors Used |
|---|
| Bio-Rad Laboratories, Inc. |
| MaxCyte, Inc. |
| Revvity, Inc. |
| Danaher Corporation |
| Thermo Fisher Scientific Inc. |
| Return on Equity Benchmarks | ||||||||
| Comparable Companies | ||||||||
| BIO.B | MXCT | RVTY | DHR | TMO | HBIO | |||
| Return On Equity | ||||||||
| Latest Twelve Months | -24% | -19% | 4% | 8% | 13% | -18% | ||
| Fiscal Year - 1 | -7% | -16% | 2% | 8% | 13% | -5% | ||
| Fiscal Year - 2 | -31% | -9% | 7% | 14% | 16% | -12% | ||
| Fiscal Year - 3 | 36% | -13% | 16% | 13% | 21% | 0% | ||
| Fiscal Year - 4 | 49% | -50% | 19% | 11% | 20% | -10% | ||
| Fiscal Year - 5 | 36% | -100% | 8% | 8% | 13% | -6% | ||
| Average | 10% | -34% | 10% | 10% | 16% | -9% | ||
| Median | 15% | -17% | 8% | 10% | 15% | -8% | ||
| Benchmarks | Ticker | |||||||
| Bio-Rad Laboratories, Inc. | NYSE:BIO.B | |||||||
| MaxCyte, Inc. | NasdaqGS:MXCT | |||||||
| Revvity, Inc. | NYSE:RVTY | |||||||
| Danaher Corporation | NYSE:DHR | |||||||
| Thermo Fisher Scientific Inc. | NYSE:TMO | |||||||
| Financial Performance | ||||||||
| Comparable Companies | ||||||||
| (in millions) | BIO.B | MXCT | RVTY | DHR | TMO | HBIO | ||
| Latest Fiscal Year | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | ||
| LTM Period | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | ||
| Revenues | ||||||||
| Latest Twelve Months | 2,567 | 39 | 2,755 | 23,875 | 42,879 | 94 | ||
| Fiscal Year | 2,567 | 39 | 2,755 | 23,875 | 42,879 | 94 | ||
| Fiscal Year - 1 | 2,671 | 41 | 2,751 | 23,890 | 42,857 | 112 | ||
| Fiscal Year - 2 | 2,802 | 44 | 3,312 | 26,643 | 44,915 | 113 | ||
| Fiscal Year - 3 | 2,923 | 34 | 3,828 | 24,802 | 39,211 | 119 | ||
| Fiscal Year - 4 | 2,546 | 26 | 2,663 | 22,284 | 32,218 | 102 | ||
| Fiscal Year - 5 | 2,312 | 22 | 2,884 | 17,911 | 25,542 | 116 | ||
| Net Income | ||||||||
| Latest Twelve Months | (1,844) | (41) | 283 | 3,899 | 6,335 | (12) | ||
| Fiscal Year | (1,844) | (41) | 283 | 3,899 | 6,335 | (12) | ||
| Fiscal Year - 1 | (637) | (38) | 180 | 4,200 | 5,995 | (3) | ||
| Fiscal Year - 2 | (3,628) | (24) | 513 | 6,222 | 6,950 | (10) | ||
| Fiscal Year - 3 | 4,254 | (19) | 889 | 5,283 | 7,725 | (0) | ||
| Fiscal Year - 4 | 3,814 | (12) | 631 | 3,510 | 6,375 | (8) | ||
| Fiscal Year - 5 | 1,759 | (13) | 228 | 2,364 | 3,696 | (5) | ||
| Total Assets | ||||||||
| Latest Fiscal Quarter Prior | 12,299 | 268 | 13,565 | 84,488 | 98,726 | 137 | ||
| Latest Fiscal Quarter | 9,364 | 239 | 12,392 | 77,542 | 97,321 | 127 | ||
| Fiscal Year | 9,364 | 239 | 12,392 | 77,542 | 97,321 | 127 | ||
| Fiscal Year - 1 | 12,299 | 268 | 13,565 | 84,488 | 98,726 | 137 | ||
| Fiscal Year - 2 | 13,502 | 287 | 14,130 | 84,350 | 97,154 | 145 | ||
| Fiscal Year - 3 | 17,799 | 284 | 15,001 | 83,184 | 95,123 | 162 | ||
| Fiscal Year - 4 | 12,973 | 52 | 7,960 | 76,161 | 69,052 | 156 | ||
| Fiscal Year - 5 | 8,009 | 30 | 6,539 | 62,082 | 58,381 | 165 | ||
| Fiscal Year - 6 | 5,611 | 24 | 5,976 | 47,833 | 56,232 | 169 | ||
| Common Equity | ||||||||
| Latest Fiscal Quarter Prior | 8,741 | 232 | 7,873 | 53,486 | 46,735 | 73 | ||
| Latest Fiscal Quarter | 6,569 | 206 | 7,667 | 49,543 | 49,584 | 63 | ||
| Fiscal Year | 6,569 | 206 | 7,667 | 49,543 | 49,584 | 63 | ||
| Fiscal Year - 1 | 8,741 | 232 | 7,873 | 53,486 | 46,735 | 73 | ||
| Fiscal Year - 2 | 9,615 | 254 | 7,383 | 48,414 | 43,978 | 72 | ||
| Fiscal Year - 3 | 13,685 | 263 | 7,141 | 41,899 | 40,793 | 83 | ||
| Fiscal Year - 4 | 9,880 | 33 | 3,735 | 36,498 | 34,507 | 77 | ||
| Fiscal Year - 5 | 5,755 | 14 | 2,814 | 28,671 | 29,675 | 82 | ||
| Fiscal Year - 6 | 4,020 | 12 | 2,585 | 28,214 | 27,586 | 83 | ||